Ubiquitin-proteasome pathway components as therapeutic targets for CNS maladies

Current Pharmaceutical Design

Volumn 11, Issue 29, 2005, Pages 3807-3828

  Upadhya, Sudarshan C ^a   Hegde, Ashok N ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Neurodegenerative diseases; Neuron; Proteasome activator; Protein aggregation; Proteolysis; Synaptic dysfunction; Ubiquitin ligase

Indexed keywords

ADENOSINE TRIPHOSPHATE DERIVATIVE; ALPHA SYNUCLEIN; ANAPHASE PROMOTING COMPLEX; ANTIOXIDANT; APOPTOSIS INHIBITOR; BORTEZOMIB; CALPASTATIN; COPPER ZINC SUPEROXIDE DISMUTASE; ELONGIN B; ELONGIN C; HUNTINGTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUTANT PROTEIN; PEPTIDASE; PEPTIDE DERIVATIVE; POLYGLUTAMINE; PRESENILIN 1; PRESENILIN 2; PRION PROTEIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN KINASE (CALCIUM,CALMODULIN) II; PROTEIN SUBUNIT; SYNTAXIN; UBIQUITIN; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNINDEXED DRUG; VON HIPPEL LINDAU PROTEIN;

ALLOSTERISM; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELL INCLUSION; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME SUBSTRATE; HAPPY PUPPET SYNDROME; HUMAN; HUNTINGTON CHOREA; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN DOMAIN; REVIEW; SYNAPSE; UBIQUITINATION;

CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 27744451306     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774580651     Document Type: Review

References (212)

1. Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003; 40: 427-46.
2. Selkoe DJ, The molecular pathology of Alzheimer's disease. Neuron 1991; 6: 487-98.
3. Lewy FH. Paralysis agitans-Pathologische anatomie. In: Lewandowsky M Ed, Handbuch der Neurologie. v. 2. Berlin: Springer-Verlag, 1992; 920-33.
4. Mori H, Kondo J, Ihara Y. Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science 1987; 235: 1641-44.
5. Lowe J, Blanchard A, Morrell K, Lennox G, Reynolds L, Billett M, et al. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease. J Pathol 1988; 155: 9-15.
6. Mayer RJ, Tipler C, Arnold J, Laszlo L, Al-Khedhairy A, Lowe J, et al. Endosome-lysosomes, ubiquitin and neurodegeneration. Adv Exp Med Biol 1996; 389: 261-9.
7. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002; 82:373-428.
8. Hegde AN, DiAntonio A. Ubiquitin and the synapse. Nature Rev Neurosci 2002; 3: 854-861.
9. Hicke L and Dunn R. Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol 2003; 19: 141-72.
10. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001; 70: 503-33.
11. Joazeiro CA, Weissman AM. RING finger proteins: mediators of ubiquitin ligase activity. Cell 2000; 102: 549-52.
12. Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ, Scheffner M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci USA 2001; 98: 1218-23.
13. Beer-Romero P, Glass S, Rolfe M. Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells. Oncogene 1997; 14: 595-602.
14. Traidej M, Chen L, Yu D, Agrawal S, Chen J. The roles of E6-AP and MDM2 in p53 regulation in human papillomavirus-positive cervical cancer cells. Antisense Nucleic Acid Drug Dev 2000; 10: 17-27.
15. Deshaies RJ. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 1999; 15: 435-67.
16. Jackson PK, Eldridge AG, Freed E, Furstenthal L, Hsu JY, Kaiser BK, et al. The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol 2000; 10: 429-39.
17. Peters JM. Subunits and substrates of the anaphase-promoting complex. Exp Cell Res 1999; 248: 339-49.
18. Peters JM. SCF and APC: the Yin and Yang of cell cycle regulated proteolysis. Curr Opin Cell Biol 1998; 10: 759-68.
19. Koegl M, Hoppe T, Schlenker S, Ulrich HD, Mayer TU, Jentsch S. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 1999; 96: 635-44.
20. Aravind L, Koonin EV. The U box is a modified RING finger - a common domain in ubiquitination. Curr Biol 2000; 10: R132-4.
21. Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 1995; 268: 533-39.
22. Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik HD, Huber R. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997; 386: 463-71.
23. Pickart CM, Cohen RE. Proteasomes and their kin: proteases in the machine age. Nat Rev Mol Cell Biol 2004; 5:177-87.
24. DeMartino GN, Moomaw CR, Zagnitko OP, Proske RJ, Ma CP, Afendis SJ, et al. PA700, an ATP-dependent activator of the 20 S proteasome, is an ATPase containing multiple members of a nu-cleotide-binding protein family. J Biol Chem 1994; 269: 20878-84.
25. Dupre S, Haguenauer-Tsapis R. Deubiquitination step in the endocytic pathway of yeast plasma membrane proteins: crucial role of Doa4p ubiquitin isopeptidase. Mol Cell Biol 2001; 21: 4482-94.
26. Katzmann DJ, Babst M, Emr SD. Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I. Cell 2001; 106:145-55.
27. Luhtala N, Odorizzi G. Bro 1 coordinates deubiquitination in the multivesicular body pathway by recruiting Doa4 to endosomes. J Cell Biol 2004; 166: 717-29.
28. Wilkinson KD. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin Cell Dev Biol 2000; 11: 141-8.
29. Amerik AY, Li SJ, Hochstrasser M. Analysis of the deubiquitinating enzymes of the yeast Saccharomyces cerevisiae. Biol Chem 2000; 381: 981-92.
30. Larsen CN, Krantz BA, Wilkinson KD. Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry 1998; 37: 3358-68.
31. Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, et al. Identification of the receptor component of the IkappaBalphaubiquitin ligase. Nature 1998; 396: 590-4.
32. Hegde AN, Goldberg AL, Schwartz JH. Regulatory subunits of cAMP-dependent protein kinases are degraded after conjugation to ubiquitin: a molecular mechanism underlying long-term synaptic plasticity. Proc Natl Acad Sci USA 1993; 90: 7436-40.
33. Chain D, Hegde AN, Yamamoto N, Liu-Marsh B, Schwartz JH. Persistent activation of cAMP-dependent protein kinase by regulated proteolysis suggests a neuron-specific function of the ubiquitin system in Aplysia. J Neurosci 1995; 15: 7592-603.
34. Hegde AN, Inokuchi K, Pei W, Casadio A, Ghirardi M, Chain DG, et al. Ubiquitin C-terminal hydrolase is an immediate-early gone essential for long-term facilitation in Aplysia. Cell 1997; 89: 115-126.
35. Kauselmann G, Weiler M, Wulff P, Jessberger S, Konietzko U, Scafidi J, et al. The polo-like protein kinases Fnk and Snk associate with a Ca (2+) and integrin-binding protein and are regulated dynamically with synaptic plasticity. EMBO J 1999; 18: 5528-39.
36. Leggett DS, Hanna J, Borodovsky A, Crosas B, Schmidt M, Baker RT, et al. Multiple associated proteins regulate proteasome structure and function. Mol Cell 2002; 10: 495-507.
37. Stone M, Hartmann-Petersen R, Seeger M, Bech-Otschir D, Wallace M, Gordon C. Uch2/Uch37 is the major deubiquitinating enzyme associated with the 26S proteasome in fission yeast. J Mol Biol 2004; 344: 697-706.
38. Yao T, Cohen RE. A cryptic protease couples deubiquitination and degradation by the proteasome. Nature 2002; 419: 403-7.
39. Weissman AM. Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2001; 2: 169-78.
40. Xie Y, Varshavsky A. Physical association of ubiquitin ligases and the 26S proteasome. Proc Nad Acad Sci USA 2000; 97: 2497-502,
41. Seeger M, Hartmann-Petersen R, Wilkinson CR, Wallace M, Samejima I, Taylor MS, et al. Interaction of the anaphase-promoting complex/cyclosome and proteasome protein complexes with multiubiquitin chain-binding proteins. J Biol Chem 2003; 278: 16791-6.
42. Verma R, Chen S, Feldman R, Schieltz; D, Yates J, Dohmen J, et al. Proteasomal proteomics: identification of nucleotide-sensitive proteasome-interacting proteins by mass spectrometric analysis of affinity-purified proteasomes. Mol Biol Cell 2000; 11: 3425-39.
43. Kleijnen MF, Shih AH, Zhou P, Kumar S, Soccio RE, Kedersha NL, et al. The hPLIC proteins may provide a link between the ubiquitination machinery and the proteasome. Mol Cell 2000; 6: 409-19.
44. Schauber C, Chen L, Tongaonkar P, Vega I, Lambertson D, Potts W, et al. Rad23 links DNA repair to the ubiquitin/proteasome pathway. Nature 1998; 391: 715-8.
45. Luders J, Demand J, Holifeld J. The ubiquitin-related BAG-1 provides a link between the molecular chaperones Hsc70/Hsp7O and the proteasome. J Biol Chem 2000; 275: 4613-7.
46. Jiang J, Ballinger CA, Wu Y, Dai Q, Cyr DM, Holifeld J, et al. CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation. J Biol Chem 2001; 276: 42938-44.
47. Meacham GC, Patterson C, Zhang W, Younger JM, Cyr DM. The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nature Cell Biol 2001; 3: 100-5.
48. Upadhya SC, Hegde AN. A potential proteasome-interacting motif within the ubiquitin-like domain of parkin and other proteins. Trends Biochem Sci 2003; 28: 280-3.
49. Sakata E, Yamaguchi Y, Kurimoto E, Kikuchi J, Yokoyama S, Yamada S, et al. Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain. EMBO Rep 2003; 4: 301-6.
50. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996; 65: 801-47.
51. Dawson SP, Arnold JE, Mayer NJ, Reynolds SE, Billett MA, Gordon C, et al. Developmental changes of the 26 S proteasome in abdominal intersegmental muscles of Manduca sexta during programmed cell death. J Biol Chem 1995; 270: 1850-58.
52. Takayanagi K, Dawson S, Reynolds SE, Mayer RJ. Specific developmental changes in the regulatory subunits of the 26 S proteasome in intersegmental muscles preceding eclosion in Manduca sexta. Biochem. Biophys Res Commun 1996; 228: 517-23.
53. Kawahara H, Yokosawa H. Intracellular calcium mobilization regulates the activity of 26 S proteasome during the metaphase-anaphase transition in the ascidian meiotic cell cycle. Dev. Biol 1994; 166: 623-33.
54. van Leeuwen FW, de Kleijn DP, van den Hurk HH, Neubauer A, Sonnemans MA, et al. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 1998; 279: 242-47.
55. Marambaud P, Ancolio K, Lopez-Perez E, Checler F. Proteasome inhibitors prevent the degradation of familial Alzheimees disease-linked presenilin 1 and potentiate A beta 42 recovery from human cells. Mol Med 1998; 4: 147-57.
56. Kim TW, Pettingell WH, Hallmark OG, Moir RD, Wasco W, Tanzi RE, Endoproteolytic cleavage and proteasomal degradation of presenilin 2 in transfected cells. J Biol Chem 1997; 272: 11006-10.
57. Keck S, Nitsch R, Grune T, Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimier's disease. J Neurochem 2003; 85: 115-22.
58. Kishino T, Lalande M, Wagstaff J. UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet 1997; 15: 70-73.
59. Matsuura T, Sutcliffe JS, Fang P, Galjaard RJ, Jiang YH, Benton CS, et al. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet 1997; 15: 74-77.
60. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-8.
61. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, et al. The ubiquitin pathway in Parkinson's disease. Nature 1098; 395: 451-2.
62. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacber A, Schneider R, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001; 293: 263-9.
63. McNaught KS, Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett 2001; 297: 191-4.
64. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997; 90: 537-48.
65. Wilson SM, Bhattacharyya B, Rachel RA, Coppola V, Tessarollo L, Householder DB, et al. Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease. Nat Genet 2002; 32: 420-5.
66. Watts RJ, Hoopfer ED, Luo L. Axon pruning during Drosophila metamorphosis: evidence for local degeneration and requirement of the ubiquitin-proteasome system. Neuron 2003; 38: 871-85.
67. Saigoh K, Wang YL, Suh JG, Yamanishi T, Sakai Y, Kiyosawa H, et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet 1999; 23: 47-51.
68. Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci 2002; 22: 2718-29.
69. Vawter MP, Crook JM, Hyde TM, Kleinman JE, Weinberger DR, Becker KG, et al. Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophr Res 2002; 58: 11-20.
70. Migheli A, Attanasio A, Vigliani MC, Schiffer D. Dystrophic neurites around amyloid plaques of human patients with Gerstmann-Straussler-Scheinker disease contain ubiquitinated inclusions. Neurosci Lett 1991; 121: 55-8.
71. Lowe J, Mayer RJ, Landon M. Ubiquitin in neurodegenerative diseases. Brain Pathol 1993; 3: 55-65.
72. Alves-Rodrigues A, Gregori L, Figueiredo-Pereira ME. Ubiquitin, cellular inclusions and their role in neurodegeneration. Trends Neurosci 1998; 21: 516-20.
73. Johnston JA, Dalton MJ, Gurney ME, Kopito RR. Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2000; 97: 12571-6.
74. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001; 292: 1552-5.
75. Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998; 143: 1883-98,
76. Layfield R, Cavey JR, Lowe J. Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders. Ageing Res Rev 2003; 2: 343-56.
77. Yamamoto N, Hegde AN, Chain DG, Schwartz JH. Activation and degradation of the transcription factor C/EBP during long-term facilitation in Aplysia. J Neurochem 1999; 73: 2415-23.
78. Burbea M, Dreier L, Dittman JS, Grunwald ME, Kaplan JM. Ubiquitin and AP180 regulate the abundance of GLR-1 glutamate receptors at postsynaptic elements in C, elegans. Neuron 2002; 35: 107-20.
79. Shenoy SK, McDonald PH, Kohout TA, Lefkowitz RJ. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science 2001; 294: 1307-13.
80. Wheeler TC, Chin LS, Li Y, Roudabush FL, Li L. Regulation of synaptophysin degradation by mammalian homologues of seven in absentia. J Biol Chem 2002; 277: 10273-82.
81. Chin LS, Vavalle JP, Li L. Staring, a novel E3 ubiquitin-protein ligase that targets syntaxin 1 for degradation. J Biol Chem 2002; 277: 35071-79.
82. Speese SD, Trotta N, Rodesch CK, Aravamudan B, Broadie K. The ubiquitin proteasome system acutely regulates presynaptic protein turnover and synaptic efficacy. Curr Biol 2003; 13: 899-910.
83. Carbone R, Fre S, Iannolo G, Belleudi F, Mancini P, Pelicci PG, et al. eps15 and cps15R are essential components of the endocytic pathway. Cancer Res 1997; 57: 5498-504.
84. Jiang YH, Armstrong D, Albrecht U, Atkins CM, Noebels JL, Eichele G, et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron 1998; 21: 799-811.
85. Muralidhar MG, Thomas JB, The Drosophila bendless gene encodes a neural protein related to ubiquitin-conjugating enzymes. Neuron 1993; 11: 253-66.
86. Oh CE, McMahon R, Benzer S, Tanouye MA. bendless, a Drosophila gene affecting neuronal connectivity, encodes a ubiquitin-conjugating enzyme homolog. J Neurosci 1994; 14: 3166-79.
87. Myat A, Henry P, McCabe V, Flintoft L, Rotin D, Tear G. Drosophila Nedd4, a ubiquitin ligase, is recruited by Commissureless to control cell surface levels of the roundabout receptor. Neuron 2002; 35: 447-59.
88. DiAntonio A, Haghighi AP, Portman SL, Lee JD, Amaranto AM, Goodman CS. Ubiquitination-dependent mechanisms regulate synaptic growth and function. Nature 2001; 412: 449-52.
89. Itoh M, Kim CH, Palardy G, Oda T, Jiang YJ, Maust D, et al. Mind bomb is a ubiquitin ligase that is essential for efficient activation of Notch signaling by Delta. Dev Cell 2003; 4: 67-82.
90. Ren Y, Zhao J, Feng J. Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. J Neurosci 2003; 23: 3316-24.
91. Bedford FK, Kittler JT, Muller E, Thomas P, Uren JM, Merle D, et al. GABA(A) receptor cell surface number and subunit stability are regulated by the ubiquitin-like protein Plic-1. Nat Neurosci 2001; 4: 908-16.
92. Buttner C, Sadder S, Leyendecker A, Laube B, Griffon N, Betz H, et al. Ubiquitination precedes internalization and proteolytic cleavage of plasma membrane-bound glycine receptors. J Biol Chem 2001; 276: 42978-85.
93. Chaturvedi K, Bandari P, Chinen N, Howells RD. Proteasome involvement in agonist-induced down-regulation of mu and delta opioid receptors. J Biol Chem 2001; 276: 12345-55.
94. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002 298: 789-91.
95. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996; 274: 99-102.
96. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-39.
97. Keller JN, Hanni KB, Markesbery WR. Impaired proteasome function in Alzheimer's disease. J Neurochem 2000; 75: 436-39.
98. Lam YA, Pickart CM, Alban A, Landon M, Jamieson C, Ramage R, et al. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc Natl Acad Sci USA 2000; 97: 9902-6.
99. Saigoh K, Wang YL, Suh JG, Yamanishi T, Sakai Y, Kiyosawa H, et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet 1999; 23: 47-51.
100. Osaka H, Wang YL, Takada K, Takizawa S, Setsuie R, Li H, et al. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet 2003; 12: 1945-58.
101. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, et al. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Atzheimer's diseases. J Biol Chem 2004; 279:13256-64.
102. Battaglia F, Trinchese F, Liu S, Walter S, Nixon RA, Arancio O. Calpain inhibitors, a treatment for Alzbeimer's disease: position paper. J Mol Neurosci 2003; 20: 357-62.
103. Cummings CJ, Reinstein E, Sun Y, Antaffy B, Jiang Y, Ciechanover A, et al. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 1999; 24: 879-92.
104. Venkatraman P, Wetzel R, Tanaka M, Nukina N, Goldberg AL. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell 2004; 14: 95-104.
105. Michalik A, Van Broeckhoven C. Proteasome degrades soluble expanded polyglutamine completely and efficiently. Neurobiol Dis 2004; 16: 202-11.
106. Lawrence AD, Hodges JR, Rosser AE, Kershaw A, ffrench-Constant C, Rubinsztein DC, et al. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 1998; 121: 1329-41.
107. Murphy KP, Carter RJ, Lione LA, Mangiarini L, Mahal A, Bates GP, et al. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J Neurosci 2000; 20: 5115-23.
108. Shelbourne PF, Killeen N, Hevner RF, Johnston HM, Tecott L, Lewandoski M, et al. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum Mot Genet 1999; 8: 763-74.
109. Morton AJ, Faull RL, Edwardson JM. Abnormalities in the synaptic vesicle fusion machinery in Huntington's disease. Brain Res Bull 2001; 56: 111-17.
110. Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 2001; 10: 1049-59.
111. Martin-Aparicio E, Yamamoto A, Hernandez F, Hen R, Avila J, Lucas JJ. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. J Neurosci 2001; 21: 8772-94.
112. Ding Q, Lewis JJ, Strum KM, Dimayuga E, Bruce-Keller AJ, Dunn JC, et al. Polyglutamine expansion, protein aggregation, proteasome activity, and neural survival. J Biol Chem 2002; 277: 13935-42.
113. Huynh DP, Del Bigio MR, Ho DH, Pulst SM. Expression of ataxin-2 in brains from normal individuals and patients with Alzheimer's disease and spinocerebellar ataxia 2. Ann Neurol 1999; 45: 232-41.
114. Ishikawa K, Watanabe M, Yoshizawa K, Fujita T, Iwamoto H, Yoshizawa T, et al. Clinical, neuropathological, and molecular study in two families with spinocerebellar ataxia type 6 (SCA6). J Neurol Neurosurg Psychiatry 1999; 67: 86-9.
115. Taylor JP, Tanaka F, Robitschek J, Sandoval CM, Taye A, Markovic-Plese S, et al. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum Mot Genet 2003; 12: 749-57.
116. Polymeropoulos MH. Genetics of Parkinson's disease. Ann N Y Acad Sci 2000; 920: 28-32.
117. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, et al, Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256-59.
118. Cookson MR. Pathways to Parkinsonism. Neuron 2003; 37: 7-10.
119. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998; 152: 879-84.
120. Healy DG, Abou-Sleiman PM, Wood NW. Genetic causes of Parkinson's disease: UCHL-1. Cell Tissue Res 2004; 318: 189-94.
121. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, et al. Familial Parkinson disease gene product parkin, is a ubiquitin-protein ligase. Nat Genet 2000; 25: 302-5.
122. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, and Dawson TM. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci USA 2000; 97: 13354-59.
123. Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med 2001; 7: 1144-50.
124. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 2001; 105: 891-902.
125. von Coelln R, Thomas B, Savitt JM, Lim KL, Sasaki M, Hess EJ, et al. Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc Nad Acad Sci USA 2004; 101: 10744-49.
126. Shen J, Cookson MR. Mitochondria and dopamine: new insights into recessive parkinsonism. Neuron 2004; 43: 301-4.
127. Imai Y, Takahashi R. How do Parkin mutations result in neurode-generation?. Curr Opin Neurobiol 2004; 14: 384-9.
128. Lotharius J, Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 2002; 3: 932-42.
129. Di Rosa G, Puzzo D, Sant'Angelo A, Trinchese F, Arancio O. Alpha-synuclein: between synaptic function and dysfunction. Histol Histopathol 2003; 18: 1257-66.
130. Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 2003; 12: 2277-91.
131. Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 2003; 278: 43628-35.
132. Huynh DP, Scoles DR, Nguyen D, Pulst SM. The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. Hum Mol Genet 2003; 12: 2587-97.
133. Bennett MC, Bishop JF, Leng Y, Chock PB, Chase TN, Mouradian MM. Degradation of alpha-synuclein by proteasome. J Biol Chem 1999; 274: 33855-58.
134. Ancolio K, Alves da Costa C, Ueda K, Checler F. Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-symiclein do not undergo proteasomal degradation in HEK293 and neuronal cells. Neurosci Lett 2000; 285: 79-82.
135. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala3OPro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998, 18: 106-8.
136. Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, Rueter SM, et al. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci 2001; 21: 8053-61.
137. Biasini E, Fioriti L, Ceglia I, Invernizzi R, Bertoli A, Chiesa R, et al. Proteasome inhibition and aggregation in Parkinson's disease: a comparative study in untransfected and transfected cells. J Neurochem 2004; 88: 545-53.
138. Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002; 36: 1007-19.
139. Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 2003; 37: 911-24.
140. Snyder H, Mensah K, Theisler C, Lee J, Matouschek A, Wolozin B. Aggregated and monomeric alpha-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function. J Biol Chem 2003; 278: 11753-9.
141. Lindersson E, Beedholm R, Hojrup P, Moos T, Gai W, Hendil KB, et al. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem 2004; 279: 12924-34.
142. Kishino T, Lalande M, Wagstaff J. UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet 1997; 15: 70-73.
143. Weeber EJ, Jiang YH, Elgersma Y, Varga AW, Carrasquillo Y, Brown SE, et al. Derangements of hippocampal calcium/calmodulin-dependent protein kinase II in a mouse model for Angelman mental retardation syndrome. J Neurosci 2003; 23: 2634-44.
144. Zanusso G, Petersen RB, Jin T, Jing Y, Kanoush R, Ferrari S, et al. Proteasomal degradation and N-terminal protease resistance of the codon 145 mutant prion protein. J Biol Chem 1999; 274: 23396-404.
145. Ma J, Lindquist S. Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science 2002; 298: 1785-8.
146. Ma J, Wollmann R, Lindquist S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 2002; 298: 1781-5.
147. Kang SC, Brown DR, Whiteman M, Li R, Pan T, Perry G, et al. Prion protein is ubiquitinated after developing protease resistance in the brains of scrapie-infected mice. J Pathol 2004; 203: 603-8.
148. Hoffman EK, Wilcox HM, Scott RW, Siman R. Proteasome inhibition enhances the stability of mouse Cu/Zn superoxide dismutase with mutations linked to familial amyotrophic lateral sclerosis. J Neurol Sci 1996; 139: 15-20.
149. Johnston JA, Dalton MJ, Gurney ME, Kopito RR. Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2000; 97: 12571-6.
150. Niwa J, Ishigaki S, Hishikawa N, Yamamoto M, Doyu M, Murata S, et al. Dorfin ubiquitylates mutant SODI and prevents mutant SODI-mediated neurotoxicity. J Biol Chem 2002; 277: 36793-8.
151. Ishigaki S, Niwa J, Ando Y, Yoshihara T, Sawada K, Doyu M, et al. Differentially expressed genes in sporadic amyotrophic lateral sclerosis spinal cords-screening by molecular indexing and subsequent cDNA microarray analysis. FEBS Lett 2002; 531: 354-8.
152. Urushitani M, Kurisu J, Tateno M, Hatakeyama S, Nakayama K, Kato S, et al. CHIP promotes proteasomal degradation of familial ALS-linked mutant SODI by ubiquitinating Hsp/Hsc70. J Neurochem 2004; 90: 231-44.
153. Urushitani M, Kurisu J, Tsukita K, Takahashi R. Proteasomal inhibition by misfolded mutant superoxide dismutase I induces selective motor neuron death in familial amyotrophic lateral sclerosis. J Neurochem 2002; 83: 1030-42.
154. Lee JP, Gerin C, Bindokas VP, Miller R, Ghadge G, Roos RP. No correlation between aggregates of Cu/Zn superoxide dismutase and cell death in familial amyotrophic lateral sclerosis. J Neurochem 2002; 82: 1229-38.
155. Vlug AS, Jaarsma D. Long term proteasome inhibition does not preferentially afflict motor neurons in organotypical spinal cord cultures. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 16-21.
156. Aquilano K, Rotilio G, Ciriolo MR. Proteasome activation and nNOS down-regulation in neuroblastoma cells expressing a Cu, Zn superoxide dismutase mutant involved in familial ALS. J Neurochem 2003; 85: 1324-35.
157. Hyun DH, Lee M, Halliwell B, Jenner P. Proteasomal inhibition causes the formation of protein aggregates containing a wide range of proteins, including nitrated proteins. J Neurochem 2003; 86: 363-73.
158. Ding Q, Keller JN. Proteasomes and proteasome inhibition in the central nervous system. Free Radic Biol Med 2001; 31: 574-84.
159. Ding Q, Reinacker K, Dimayuga E, Nukala V, Drake J, Butterfield DA, et al. Role of the proteasome in protein oxidation and neural viability following low-level oxidative stress. FEBS Lett 2003; 546: 228-32.
160. Stohwasser R, Giesebrecht J, Kraft R, Muller EC, Hausler KG, Kettenmann H, et al. Biochemical analysis of proteasomes from mouse microglia: induction of immunoproteasomes by interferon-gamma and lipopolysaccharide. Glia 2000; 29: 355-65.
161. Sherman MY, Goldberg AL. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 2001; 29: 15-32.
162. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-moleculle antagonists of MDM2. Science 2004; 303: 844-8.
163. Gosink MM, Vierstra RD. Redirecting the specificity of ubiquitination by modifying ubiquitin-conjugating enzymes. Proc Natl Acad Sci USA 1995; 92: 9117-21.
164. Oyake D, Nishikawa H, Koizuka I, Fukuda M, Ohta T. Targeted substrate degradation by an engineered double RING ubiquitin ligase. Biochem Biophys Res Commun 2002; 295: 370-5.
165. Zhou P, Bogacki R, McReynolds L, Howley PM. Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins. Mol Cell 2000; 6: 751-6.
166. Zhang J, Zheng N, Zhou P. Exploring the functional complexity of cellular proteins by protein knockout. Proc Natl Acad Sci USA 2003; 100: 14127-32.
167. Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci USA 2001; 98: 8554-9,
168. Sakamoto KM, Kim KB, Verma R, Ransick A, Stein B, Crews CM, et al. Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. Mol Cell Proteomics 2003; 2: 1350-58.
169. Keller JN, Huang FF, Zhu H, Yu J, Ho YS, Kindy TS. Oxidative stress-associated impairment of proteasome activity during ischemia-reperfusion injury. J Cereb Blood Flow Metab 2000, 20: 1467-73.
170. Hyun DH, Lee MH, Halliwell B, Jenner P. Proteasomal dysfunction induced by 4-hydroxy-2, 3-trans-nonenal, an end-product of lipid peroxidation: a mechanism contributing to neurodegeneration?. J Neurochem 2002; 83: 360-70.
171. Grune T, Blasig IE, Sitte N, Roloff B, Haseloff R, Davis KJ. Peroxynitrite increases the degradation of aconitase and other cellular proteins by proteasome. J Biol Chem 1998; 273: 10857-62.
172. Rideout HJ, Larsen KE, Sulzer D, Stefanis L. Proteasomal inhibition leads to formation of ubiquitin/alpha-synucleinimmunoreactive inclusions in PC12 cells. J Neurochem 2001; 78: 899-908.
173. Pickart CM. Targeting of substrates to the 26S proteasome. FASEB J 1997; 11: 1055-66.
174. Armon T, Ganoth D, Hershko A. Assembly of the 26 S complex that degrades proteins ligated to ubiquitin is accompanied by the formation of ATPase activity. J Biol Chem 1990; 265: 20723-6.
175. DeMartino GN, Moomaw CR, Zagnitko OP, Proske RJ, Chu-Ping M, Afendis SJ, et al. PA700, an ATP-dependent activator of the 20 S proteasome, is an ATPase containing multiple members of a nucleotide-binding protein family. J Biol Chem 1994; 269: 20878-84.
176. Hoffman L, Rechsteiner M. Activation of the multicatalytic; protease. The 11 S regulator and 20 S ATPase complexes contain distinct 30-kilodalton subunits. J Biol Chem 1994; 269: 16890-5.
177. Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, et al, Anatomic and disease specificity of NADH CoQI reductase (complex 1) deficiency in Parkinson's disease. J Neurochem 1990; 55: 2142-5.
178. Kohler A, Cascio P, Leggett DS, Woo KM, Goldberg AL, Finley D. The axial channel of the proteasome core particle is gated by the Rpt2 ATPase and controls both substrate entry and product release. Mol Cell 2001; 7: 1143-52.
179. Rubin DM, Glickman MH, Larsen CN, Dhruvakumar S, Finley D. Active site mutants in the six regulatory particle ATPases reveal multiple roles for ATP in the proteasome. EMBO J 1998; 17: 4909-19.
180. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 2003; 179: 38-46.
181. Hoffman L, Rechsteiner M. Effects of nucleotides on assembly of the 26S proteasome and degradation of ubiquitin conjugates. Mol Biol Rep 1997; 24: 13-6.
182. Asai A, Tanahashi N, Qiu JH, Saito N, Chi S, Kawahara N, et al. Selective proteasomal dysfunction in the hippocampal CA1 region after transient forebrain ischemia. J Cereb Blood Flow Metab 2002; 22: 705-10.
183. Kamikubo T, Hayashi T. Changes in proteasome activity following transient ischemia. Neurochem Int 1996; 28: 209-12.
184. Seo H, Sonntag KC, Isacson O. Generalized brain and skin proteasome inhibition in Huntington's disease. Ann Neurol 2004; 56: 319-28.
185. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, et al. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 2002; 22: 7006-15.
186. Lam YA, Lawson TG, Velayutham M, Zweier JL, Pickart CM. A proteasomal ATPase subunit recognizes the polyubiquitin degradation signal. Nature 2002; 416: 763-7.
187. Chu-Ping M, Vu JH, Proske RJ, Slaughter CA, DeMartino GN. Identification, purification, and characterization of a high molecular weight, ATP-dependent activator (PA700) of the 20 S proteasome. J Biol Chem 1994; 269: 3539-47.
188. Adams GM, Falke S, Goldberg AL, Slaughter CA, DeMartino GN, Gogol EP. Structural and functional effects of PA700 and modulator protein on proteasomes. J Mol Biol 1997; 273: 646-57.
189. Ditzel L, Lowe J, Stock D, Stetter KO, Huber H, Huber R, et al. Crystal structure of the thermosome, the archaeal chaperonin and homolog of CCT. Cell 1998; 93: 125-38.
190. Wigley WC, Fabunmi RP, Lee MG, Marino CR, Muallem S, De-Martino GN, et al. Dynamic association of proteasomal machinery with the centrosome. J Cell Biol 1999; 145: 481-90.
191. Bercovich B, Stancovski I, Mayer A, Blumenfeld N, Laszlo A, Schwartz AL, et al. Ubiquitin-dependent degradation of certain protein substrates in vitro requires the molecular chaperone HsC70. J Biol Chem 1997; 272: 9002-10.
192. Doong H, Rizzo K, Fang S, Kulpa V, Weissman AM, Kohn EC. CAIR-1/BAG-3 abrogates heat shock protrin-70 chaperone complex-mediated protein degradation: accumulation of poly-ubiquitinated Hsp90 client proteins. J Biol Chem 2003; 278: 28490-500.
193. Shimura H, Miura-Shimura Y, Kosik KS. Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J Biol Chem 2004; 279: 17957-62.
194. Shimura H, Schwartz D, Gygi SP, Kosik KS. CHIP-Hsc7O complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem 2004; 279: 4869-76.
195. Liu CW, Corboy MJ, DeMartino GN, Thomas PJ. Endoproteolytic activity of the proteasome. Science 2003; 299: 408-11.
196. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004; 22: 304-11.
197. Dubiel W, Pratt G, Ferrell K, Rechsteiner M. Purification of an 11 S regulator of the multicatalytic protease. J Biol Chem 1992; 267: 22369-77.
198. Ma CP, Willy PJ, Slaughter CA, DeMartino GN. PA28, an activator of the 20 S proteasome, is inactivated by proteolytic modification at its carboxyl terminus. J Biol Chem 1993; 268: 22514-9.
199. Gray CW, Slaughter CA, DeMartino GN. PA28 activator protein forms regulatory caps on proteasome stacked rings. J Mol Biol 1994; 236: 7-15.
200. Zhang Z, Krutchinsky A, Endicott S, Realini C, Rechsteirier M, Standing KG. Proteasome activator 11S REG or PA28: recombinant REG alpha/REG beta hetero-oligomers are heptamers. Biochemistry 1999; 38, 5651-8.
201. Orlowski M, Wilk S. A multicatalytic protease complex from pituitary that forms enkephalin and enkephalin- containing peptides. Biochem Biophys Res Common 1981; 101: 814-22.
202. Pereira ME, Yu B, Wilk S. Enzymatic changes of the bovine pituitary multicatalytic proteinase complex, induced by magnesium ions. Arch Biochem Biophys 1992; 294: 1-8.
203. Mellgren RL. Interaction of human erythrocyte multicatalytic proteinase with polycations. Biochim Biophys Acta 1990; 1040: 28-34.
204. Tanaka K, Li K, Ichihara A, Waxman L, Goldberg AL. A high molecular weight protease in the cytosol of rat liver. I. Purification, enzymological properties, and tissue distribution. J Biol Chem 1986; 261: 15197-203.
205. Dahlmann B, Becher B, Sobek A, Ehlers C, Kopp F, Kuehn L. In vitro activation of the 20S proteasome. Enzyme Protein 1993; 47: 274-84.
206. Ruiz de Mena I, Mahillo E, Arribas J, Castana JG. Kinetic mechanism of activation by cardiolipin (diphosphatidylglycerol) of the rat liver multicatalytic proteinase. Biochem J. 1993; 296 ( Pt 1): 93-7.
207. Wilk S, Chen WE. Synthetic peptide-based activators of the proteasome. Mol Biol Rep 1997; 24: 119-24.
208. Kukan M. Emerging roles of proteasomes in ischemia-reperfusion injury of organs. J Physiol Pharmacol 2004; 55: 3-15.
209. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994; 78: 773-85.
210. Asanuma M, Miyazaki I, Ogawa N. Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases. Curr Pharm Design 2004; 10(6): 695-700.
211. Campiani G, Fattorusso C, De Angelis M, Catalanotti B, Butini S, Fattorusso R, et al. Neuronal high-affinity sodium-dependent glutamate transporters (EAATs): targets for the development of novel therapeutics against neurodegenerative diseases. Curr Pharm Design 2003; 9(8): 599-625.
212. Tozser J, Oroszlan S. Proteolytic events of HIV-1 replication as targets for therapeutic intervention. Curr Pharm Design 2003; 9(22): 1803-15.